BioSpace News Archive

The American Urological Association announced Thomas F. Stringer, MD, FACS, as Treasurer-elect, a position he will assume in May 2020.

An Innovative Approach Leveraging the Power of AI and Technology to Deliver High-Touch Navigation

Incyte Corporation announced that it will present at the Credit Suisse 28th Annual Healthcare Conference on Tuesday, November 12, 2019 at 8:35 am / 10:35 am in Scottsdale, Arizona.

InVivo Therapeutics Holdings Corp. (NVIV) today announced that a total of five patients have been enrolled into The INSPIRE 2.0 Study (InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury), bringing the study to 25% completion of targeted enrollment

CytoSorbents Corporation announced that the U.S. Air Force Materiel Command has awarded the Company a two-year contract valued at up to $2,959,747 as part of the Rapid Innovation Fund to advance its program, entitled “K+ontrol Renal Support System for Reduction of Hyperkalemia,” towards a U.S. clinical trial designed to support U.S. FDA regulatory approval..

Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, November 6, 2019 to report its third quarter 2019 financial results and provide a corporate update.

Highly aggressive KRAS-mutated tumors account for ~50% of metastatic colorectal cancer (mCRC); no targeted treatments available and response to standard-of-care is only 5%

VBI Vaccines Inc. (Nasdaq: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that the company’s abstract titled, “Rapid Increase in Anti-HBsAg Titers and Higher Seroprotection Rates in Adults Immunized with Sci-B-Vac Compared to a Monovalent Hepatitis B Vaccine: Results from PROTECT – a Double-Blind, Randomized, Controlled, Phase-3 Study,

The BIO Investor Forum will be held October 22-23, 2019.

Dr. Robbins brings 20 years of experience as an executive leading and advising innovative biotechnology companies through all stages of development.